Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5849519 | 1.00 | MEN1 (0.40) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL22787086 | 0.93 | MEN1 (0.47) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL22787067 | 0.93 | MEN1 (0.47) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL13455405 | 0.91 | MEN1 (0.44) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL6714850 | 0.91 | MEN1 (0.44) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL948840 | 0.89 | MEN1 (0.43) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| Ammonia Solution, Strong SCHEMBL23857767 | 0.87 | MEN1 (0.42) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL22787057 | 0.86 | MEN1 (0.47) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL13455407 | 0.85 | MEN1 (0.39) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL23544814 | 0.82 | MEN1 (0.46) | MEN1KMT2AKDM4CL3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116217573-B | Vertical monomolecular film field effect control switch and preparation method thereof | 南开大学 | 2024-08-30 | — | — | CN | disclosed |
| CN-116217573-A | Vertical monomolecular film field effect control switch and preparation method thereof | 南开大学 | 2023-06-06 | — | — | CN | disclosed |
| US-20180009829-A1 | GOLD NANOPARTICLES AND METHODS OF MAKING AND USING GOLD NANOPARTICLES | UNIVERSITY OF OREGON (US) | 2018-01-11 | — | — | US | disclosed |
| US-9771380-B2 | Gold nanoparticles and methods of making and using gold nanoparticles | UNIVERSITY OF OREGON (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771380-B2 | Gold nanoparticles and methods of making and using gold nanoparticles | UNIVERSITY OF OREGON (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771380-B2 | Gold nanoparticles and methods of making and using gold nanoparticles | UNIVERSITY OF OREGON (US) | 2017-09-26 | — | — | US | disclosed |
| EP-2821385-B1 | Method for the preparation of therapeutically valuable triphenylbutene derivatives | HORMOS MEDICAL LTD (FI) | 2016-07-27 | — | — | EP | disclosed |
| US-20150353580-A1 | GOLD NANOPARTICLES AND METHODS OF MAKING AND USING GOLD NANOPARTICLES | UNIVERSITY OF OREGON | 2015-12-10 | — | — | US | disclosed |
| US-20150353580-A1 | GOLD NANOPARTICLES AND METHODS OF MAKING AND USING GOLD NANOPARTICLES | UNIVERSITY OF OREGON | 2015-12-10 | — | — | US | disclosed |
| US-20150353580-A1 | GOLD NANOPARTICLES AND METHODS OF MAKING AND USING GOLD NANOPARTICLES | UNIVERSITY OF OREGON | 2015-12-10 | — | — | US | disclosed |
| CN-101636372-B | Method for the preparation of therapeutically valuable triphenylbutene derivatives | HORMOS MEDICAL LTD (FI) | 2013-03-27 | — | — | CN | disclosed |
| EP-2518039-A9 | Method for the preparation of therapeutically valuable triphenylbutene derivatives | Hormos Medical Ltd. (FI) | 2013-02-13 | — | — | EP | disclosed |
| EP-2518039-A1 | Method for the preparation of therapeutically valuable triphenylbutene derivatives | Hormos Medical Ltd. (FI) | 2012-10-31 | — | — | EP | disclosed |
| US-8293947-B2 | Method for the preparation of therapeutically valuable triphenylbutene derivatives | HORMOS MEDICAL LTD. (FI) | 2012-10-23 | — | — | US | disclosed |
| US-20110015448-A1 | METHOD FOR THE PREPARATION OF THERAPEUTICALLY VALUABLE TRIPHENYLBUTENE DERIVATIVES | HORMOS MEDICAL LTD. | 2011-01-20 | — | — | US | disclosed |
| US-7812197-B2 | Alkylation a corresponding alcoholic compound | HORMOS MEDICAL LTD. (FI) | 2010-10-12 | — | — | US | disclosed |
| EP-2121553-A1 | METHOD FOR THE PREPARATION OF THERAPEUTICALLY VALUABLE TRIPHENYLBUTENE DERIVATIVES | Hormos Medical Ltd. (FI) | 2009-11-25 | — | — | EP | disclosed |
| US-20080207956-A1 | Alkylation a corresponding alcoholic compound | DUCHESNAY INC. (CA) | 2008-08-28 | — | — | US | disclosed |
| WO-2008099059-A1 | METHOD FOR THE PREPARATION OF THERAPEUTICALLY VALUABLE TRIPHENYLBUTENE DERIVATIVES | HORMOS MEDICAL LTD (FI) | 2008-08-21 | — | — | WO | disclosed |
| WO-2002032963-A1 | IMMUNOADJUVANT SYSTEMS | ALCHEMIA PTY LTD (AU) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180009829-A1 | GOLD NANOPARTICLES AND METHODS OF MAKING AND USING GOLD NANOPARTICLES | MPO, SPR, CD63 | MEN1 4530/4885KMT2A 2923/4885KDM4C 2892/4885 |
| US-20080207956-A1 | Alkylation a corresponding alcoholic compound | CYP2E1, PNMT, ADH1A | MEN1 2295/4885KMT2A 162/4885KDM4C 236/4885 |
| US-20110015448-A1 | METHOD FOR THE PREPARATION OF THERAPEUTICALLY VALUABLE TRIPHENYLBUTENE DERIVATIVES | PDGFRB, TPMT, SIRT3 | MEN1 2474/4885KMT2A 1897/4885KDM4C 2574/4885 |
| US-20150353580-A1 | GOLD NANOPARTICLES AND METHODS OF MAKING AND USING GOLD NANOPARTICLES | MPO, SPR, CD63 | MEN1 4530/4885KMT2A 2923/4885KDM4C 2892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.